Want to see EDIT full AI Analyst Report?
Top Page
Editas Medicine
(NASDAQ:EDIT)
Select Model
Select Model
Rating:49Neutral
Price Target:
$3.00
▼(-14.04% Downside)
Action:Reiterated
Date:07/04/26
The score is held down primarily by weak financial performance—large ongoing losses, meaningful cash burn, and a sharply eroded equity base with higher leverage. Technicals are supportive (price above key averages and positive MACD) but look overextended (RSI/Stoch elevated). Corporate events improve liquidity runway via financing and add positive preclinical program momentum, but dilution and early-stage risk keep the overall rating below average.
Positive Factors
Lead program EDIT-401 shows durable, high-magnitude preclinical efficacy
Robust, durable LDL-C and ApoB reductions in primates plus favorable pre-IND feedback materially de-risks the in vivo EDIT-401 program. If replicated in humans, a one-time, best-in-class therapy would create long-term commercial optionality and validate the company’s hepatic upregulation platform.
Negative Factors
High cash burn and negative free cash flow
Sustained ~$141M annual cash burn means cash consumption remains high relative to current resources. Even with recent financing, continued negative FCF requires disciplined spending or repeat capital raises, which can dilute shareholders and constrain long-term investment flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Lead program EDIT-401 shows durable, high-magnitude preclinical efficacy
Robust, durable LDL-C and ApoB reductions in primates plus favorable pre-IND feedback materially de-risks the in vivo EDIT-401 program. If replicated in humans, a one-time, best-in-class therapy would create long-term commercial optionality and validate the company’s hepatic upregulation platform.
Read all positive factors
Editas Medicine Key Performance Indicators (KPIs)
Any
Operating Expense Breakdown
Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment, crucial for understanding Editas Medicine's focus on innovation and operational strategy.
Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment, crucial for understanding Editas Medicine's focus on innovation and operational strategy.
Data provided by:
The Fly
The FlyEditas Medicine (EDIT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$457.32M
Dividend YieldN/A
Average Volume (3M)1.70M
Price to Earnings (P/E)―
Beta (1Y)2.41
Revenue Growth7.97%
EPS Growth59.82%
CountryUS
Employees87
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.23
Shares Outstanding153,461,840
10 Day Avg. Volume1,781,207
30 Day Avg. Volume1,697,905
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)6.67
Price to Sales (P/S)4.49
P/FCF Ratio-1.10
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.20Price Target Upside106.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.99
Revenue Forecast (FY)$14.33M
Editas Medicine Business Overview & Revenue Model
Company Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its l...
How the Company Makes Money
Editas Medicine generates revenue primarily through collaboration-related income rather than product sales, as it has historically been a clinical-stage company without commercialized drugs. Its revenue model centers on (1) upfront payments and li...
Editas Medicine Earnings Call Summary
Earnings Call Date:Aug 07, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call highlighted significant progress in both clinical trials and in vivo pipeline development. Financial stability was assured despite a higher burn rate. However, challenges such as increased expenses and regulatory issues around fertility support present hurdles. Overall, the company's advancements in gene editing and robust clinical trial outcomes provide a positive outlook.Positive Updates
Reni-cel Clinical Trials Progress
Completed adolescent cohort enrollment for the RUBY trial, and adult cohort enrollment in the EdiTHAL trial. Clinical data from RUBY and EdiTHAL trials show promising results with all patients free from vaso-occlusive events and a high level of fetal hemoglobin.
Negative Updates
Increased Burn Rate
Higher burn rate this quarter due to increased external R&D expenses, primarily related to clinical and manufacturing costs.
Read all updates
Q2-2024 Updates
Positive
Negative
Reni-cel Clinical Trials Progress
Completed adolescent cohort enrollment for the RUBY trial, and adult cohort enrollment in the EdiTHAL trial. Clinical data from RUBY and EdiTHAL trials show promising results with all patients free from vaso-occlusive events and a high level of fetal hemoglobin.
Read all positive updates
Company Guidance
During the Editas Medicine Q2 2024 earnings call, CEO Gilmore O'Neill outlined the company's strategic progress, emphasizing three main pillars: advancing reni-cel towards BLA and commercialization, building a differentiated in vivo editing pipeline, and enhancing business development with a focus on intellectual property. The RUBY trial data for sickle cell disease showed promising results, with 18 patients having follow-up periods ranging from 2.4 to 22.8 months and demonstrating robust anemia correction. The EdiTHAL trial for beta-thalassemia included data from 7 patients with 4.1 to 12.8 months follow-up. Financially, Editas reported cash, cash equivalents, and marketable securities totaling $318 million as of June 30, 2024, with a burn rate increase due to R&D expenses. They expect to fund operations into 2026. The company is also on track to establish in vivo preclinical proof of concept by year-end, with a focus on leveraging indel technology for gene upregulation, targeting rare and orphan diseases initially.Editas Medicine Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.69M | 40.52M | 32.31M | 78.12M | 19.71M | 25.54M |
| Gross Profit | 2.25M | 40.52M | -166.93M | 72.06M | 13.38M | 20.49M |
| EBITDA | -100.08M | -148.61M | -233.11M | -147.16M | -214.09M | -187.45M |
| Net Income | -108.95M | -160.06M | -237.09M | -153.22M | -220.43M | -192.50M |
Balance Sheet | ||||||
| Total Assets | 149.34M | 186.53M | 341.59M | 499.15M | 514.32M | 677.48M |
| Cash, Cash Equivalents and Short-Term Investments | 123.65M | 146.65M | 269.91M | 323.11M | 344.27M | 499.85M |
| Total Debt | 71.97M | 76.71M | 35.03M | 48.54M | 43.95M | 26.38M |
| Total Liabilities | 144.93M | 159.25M | 207.31M | 150.06M | 153.64M | 123.84M |
| Stockholders Equity | 4.41M | 27.29M | 134.27M | 349.10M | 360.68M | 553.64M |
Cash Flow | ||||||
| Free Cash Flow | -141.09M | -165.85M | -219.11M | -136.90M | -181.47M | -171.78M |
| Operating Cash Flow | -140.50M | -165.24M | -210.28M | -132.18M | -177.35M | -163.80M |
| Investing Cash Flow | 82.34M | 138.67M | 162.15M | -3.73M | 114.07M | -54.47M |
| Financing Cash Flow | 41.91M | 40.47M | 56.03M | 118.04M | 1.28M | 282.11M |
Editas Medicine Technical Analysis
Neutral
3.49
Price Trends
2.95
Negative
2.82
Positive
2.69
Positive
Market Momentum
0.03
Positive
44.12
Neutral
12.22
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EDIT, the sentiment is Neutral. The current price of 3.49 is above the 20-day moving average (MA) of 3.15, above the 50-day MA of 2.95, and above the 200-day MA of 2.69, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 44.12 is Neutral, neither overbought nor oversold. The STOCH value of 12.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EDIT.
Editas Medicine Risk Analysis
Editas Medicine disclosed 73 risk factors in its most recent earnings report. Editas Medicine reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Editas Medicine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $457.32M | -2.35 | -677.38% | ― | 7.97% | 59.82% | |
49 Neutral | $980.22M | -0.03 | 87.31% | ― | ― | -1004.74% | |
49 Neutral | $163.65M | -1.14 | -100.13% | ― | 12.96% | 12.51% | |
48 Neutral | $304.73M | -4.44 | 85.78% | ― | 20.08% | 14.06% | |
42 Neutral | $72.98M | -1.29 | -2748.16% | ― | ― | 43.68% | |
41 Neutral | $190.72M | -3.89 | -80.61% | ― | 43.21% | -15.55% |
* Healthcare Sector Average
EDIT
Editas Medicine
2.88
-0.27
-8.57%
CLLS
Cellectis SA
2.60
0.77
42.08%
FHTX
Foghorn Therapeutics
5.19
-0.91
-14.92%
ELTX
Elicio Therapeutics
3.04
-6.20
-67.10%
VOR
Vor Biopharma
17.45
-23.55
-57.44%
CRBU
Caribou Biosciences
1.62
-0.45
-21.74%
Editas Medicine Corporate Events
Executive/Board ChangesShareholder Meetings
Editas Medicine Shareholders Back Board, Pay and Auditor
Positive
Jun 18, 2026
At its June 17, 2026 annual meeting, Editas Medicine stockholders elected Bernadette Connaughton and Elliott Levy, M.D., as Class I directors to serve until the 2029 annual meeting, reinforcing the company’s board leadership and governance c...
Business Operations and StrategyPrivate Placements and Financing
Editas Medicine Raises Capital Through Public Equity Offering
Positive
May 26, 2026
On May 26, 2026, Editas Medicine, Inc. priced an underwritten public offering of 55,555,556 shares of common stock and accompanying warrants at $2.25 per share-and-warrant unit, for expected gross proceeds of about $125 million. All securities are...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Editas Medicine Suspends Existing At-The-Market Offering Prospectus
Negative
May 26, 2026
On May 26, 2026, Editas Medicine, Inc. suspended and terminated the March 21, 2025 prospectus supplement tied to its at-the-market equity offering program with TD Securities (USA) LLC, also known as TD Cowen, while keeping the underlying sales agr...
Business Operations and StrategyProduct-Related Announcements
Editas Showcases Promising EDIT-401 Data for Hyperlipidemia
Positive
May 26, 2026
On May 25, 2026, Editas Medicine presented new preclinical data at the 94th European Atherosclerosis Society Congress in Athens showing that a single dose of its lead in vivo candidate EDIT-401 produced rapid, dose-dependent reductions of about 90...
Business Operations and StrategyProduct-Related Announcements
Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data
Positive
May 14, 2026
On May 14, 2026, at the American Society of Gene and Cell Therapy Annual Meeting, Editas Medicine reported new preclinical data for its lead in vivo candidate EDIT-401 as a potential one-time treatment for hyperlipidemia, showing 90% or greater me...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.